Public perceptions related to healthcare preparedness to anti-amyloid therapies for Alzheimer's Disease in Japan.

ABSTRACT:

Background

The approval of lecanemab, an anti-amyloid therapy for Alzheimer's disease (AD), necessitates addressing healthcare preparedness for disease-modifying treatment (DMT) to ensure appropriate, safe, and sustainable drug administration. Understanding public perceptions on this matter is crucial. We aimed to assess discrepancies and similarities in the perceptions of Japanese trial-ready cohort study ('J-TRC webstudy') participants and clinical specialists in the fields of dementia treatment and radiology, concerning affairs related to challenges in DMT preparedness.

Methods

This was a cross-sectional prospective observational study conducted in November-December 2023. The J-TRC webstudy participants were invited to participate in an online survey using Google Forms, a

SUBMITTER: Sato K 

PROVIDER: S-EPMC11448067 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature